ethyl (R)-2-methylbutanoate | 40917-00-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (R)-2-methylbutanoate
• 英文别名: (R)-2-methyl-butyric acid ethyl ester；(R)-2-Methyl-buttersaeure-aethylester；(R)-2-Methylbuttersaeureethylester；ethyl (2R)-2-methylbutanoate
• CAS: 40917-00-8
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: HCRBXQFHJMCTLF-ZCFIWIBFSA-N

物化性质

• 沸点：
  135.1±8.0 °C(Predicted)
• 密度：
  0.879±0.06 g/cm3(Predicted)
• LogP：
  2.158 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乙醇 、 (S)-2-甲基丁酰氯 生成 ethyl (R)-2-methylbutanoate
  参考文献：
  名称：

  749.取代的丙二酸衍生物的脱羧机理

  摘要：

  DOI：

  10.1039/jr9510003407

文献信息

• Asymmetric Hydrogenation Routes to Deoxypolyketide Chirons
  作者：Jianguang Zhou、James W. Ogle、Yubo Fan、Vorawit Banphavichit(Bee)、Ye Zhu、Kevin Burgess

  DOI：10.1002/chem.200700390

  日期：2007.8.27

  selectivity; this is the first time this has been achieved in any asymmetric synthesis of a deoxypolyketide fragment. Throughout, diastereoselectivities of the crude material in the syntheses of alpha,omega-functionalized internal deoxypolyketide fragments were in excess of 11:1.0 and chromatographically purified samples could be isolated in high yields with dr (dr=diastereomeric ratio) values consistently

  进行单烯和二烯的不对称氢化以获得末端脱氧聚酮片段A以及相应的内部Chiron B和C。整个使用手性N-杂环卡宾催化剂1。简单的单烯的氢化反应的适度选择性转为制备末端脱氧聚酮化合物片段的高选择性，其中使用两个氢化反应或一个和一个光学纯的起始原料。奇怪的是，α，β-不饱和酯加氢的表面选择性一直与先前研究中苯乙烯和苯乙烯衍生物的观察结果相反，并且与这项研究中紧密相关的烯丙醇和醚衍生物也一直相反。通过使用DFT计算得出了这种不同行为的合理机制。看来酯衍生物异常立体选择性的起源是酯羰基的瞬时金属配位，而没有证据表明烯丙基醇或醚配位。发展为α，ω-官能化的内部脱氧聚酮片段的途径是非常实用的。这些始于将罗氏酯转化为烯烃，在一种情况下，转化为二烯衍生物。在这些底物的氢化中主要控制催化剂，但是存在显着的“底物载体”（我们用来描述底物对催化剂控制的反应的影响的术语）。这是通过最小化1,3-烯丙基菌株以及在某些
• METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE
  申请人：API Corporation

  公开号：US20160083341A1

  公开（公告）日：2016-03-24

  According to the present invention, it becomes possible to perform a process for converting into an α-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a process that is routed through a compound represented by general formula (3) to a compound represented by general formula (6). Particularly, by employing a process that is routed through a compound represented by general formula (7-2), it becomes possible to detach a tert-butyl protection group in a simple manner and to produce the compound represented by general formula (1) with high purity. Furthermore, by employing a process that is routed through tert-butylthiomethanol or a process that is routed through a compound represented by general formula (9), it becomes possible to produce a compound represented by general formula (2) without generating bischloromethylether that is an oncogenic substance. In the production of an α-substituted-D-cysteine or a salt thereof, it becomes possible to perform a process for converting the compound represented by general formula (2) into a compound represented by general formula (3S) in one step by allowing an enzyme or the like to act on the compound represented by general formula (2).

  根据本发明，通过采用经由一种化合物（通式（3）表示）到一种通式（6）表示的化合物的过程，可以以低成本和工业化规模进行将其转化为通式（1）表示的α-取代半胱氨酸或其盐的过程。特别是，通过采用经由一种通式（7-2）表示的化合物的过程，可以简单地去除叔丁基保护基，并以高纯度生产通式（1）表示的化合物。此外，通过采用经由叔丁基硫代甲醇或经由一种通式（9）表示的化合物的过程，可以生产通式（2）表示的化合物，而不产生致癌物质双氯甲醚。在生产α-取代-D-半胱氨酸或其盐时，可以通过允许酶或类似物作用于通式（2）表示的化合物，一步将其转化为通式（3S）表示的化合物。
• A Comparison between Oxazoline-imidazolinylidene, -imidazolylidine, -benzimidazolylidene Hydrogenation Catalysts
  作者：Sakunchai Khumsubdee、Yubo Fan、Kevin Burgess

  DOI：10.1021/jo4013783

  日期：2013.10.4

  benzimidazolylidene complexes 1a–c were prepared and tested in asymmetric hydrogenations of a series of largely unfunctionalized alkenes. Similarities and differences in the catalytic performance of these complexes were rationalized in terms of the predicted mechanisms of these reactions, and their relative tendencies to generate protons under the hydrogenation conditions.

  制备了咪唑啉基、咪唑基、苯并咪唑基配合物1a - c，并在一系列很大程度上未官能化的烯烃的不对称氢化中进行了测试。根据这些反应的预测机制以及它们在氢化条件下产生质子的相对趋势，这些配合物催化性能的异同被合理化。
• Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
  申请人：Arimilli N. Murty

  公开号：US20070010489A1

  公开（公告）日：2007-01-11

  Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

  本发明揭示了具有HIV蛋白酶抑制剂性质的膦酸酯取代化合物，其具有作为治疗剂和其他工业用途的用途。该组合物抑制5型HIV蛋白酶活性和/或在治疗艾滋病和其他抗病毒感染方面具有治疗作用，以及在检测HIV蛋白酶方面的检测中有用。
• CHEMICAL COMPOUNDS
  申请人：SYNGENTA LIMITED

  公开号：US20160200708A1

  公开（公告）日：2016-07-14

  The invention relates to pyrrolone compounds of the formula (I) wherein X, R 1 , R 2 , R 3 , R a , R c and R d are as defined in the specification. Furthermore, the present invention relates to processes and intermediates for making compounds of formula (I), to herbicidal compositions comprising these compounds and to methods of using these compounds to control plant growth.

  该发明涉及式(I)的吡咯烷化合物，其中X、R1、R2、R3、Ra、Rc和Rd如规范中所定义。此外，本发明涉及制备式(I)化合物的过程和中间体，包括这些化合物的除草剂组合物，以及使用这些化合物控制植物生长的方法。